Roberto Carmagnani Pestana

Representation of Patients From South America in Sarcoma Clinical Trials

Tomás Costa Bignoto, Isadora Yasbick Spricido, Juliana Rodrigues Beal, Renée Zon Filippi et autres

This cross-sectional study uses clinical trial data, US and European oncology drug approval data, and health care professional survey data to examine the representation of South American patients in sarcoma clinical trials.

br, ar, cl, pe, co (code pays fourni par la source)

Revisiting prognostic biomarkers in gastrointestinal stromal tumor: the potential role of ETV1 polymorphisms

Roberto Carmagnani Pestana, Douglas Dias e Silva

br (code pays fourni par la source)

Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development

Denis Horgan, Zorana Maravic, Ken Mastris, Hadi Mohamad Abu Rasheed et autres

PURPOSE Global oncology trials face increasing scrutiny over regional enrollment imbalances, as regulatory agencies such as the US Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency demand data reflective of population diversity. This push is grounded in …

in, be, gb, us, Algérie, Égypte, mx, br (code pays fourni par la source)

Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: a perspective on evidence gaps

Isadora Yasbick Spricido, Tomás Costa Bignoto, Juliana Rodrigues Beal, Douglas Dias e Silva et autres

Post-recurrence treatment plays a crucial role in determining long-term outcomes in oncology, yet it is frequently underreported in clinical trials. A review of randomized, controlled trials (RCTs) across multiple cancers found that 43% failed to report recurrence data. This limitation is particularly …

br, us (code pays fourni par la source)

Predicting 30-day unplanned readmissions in patients with cancer in a Brazilian hospital: a Machine Learning approach

Nickolas Stabellini, Marília Melo Favalesso, Cláudia Szlejf, Cesar Gomes Miguel et autres

OBJECTIVE: This study aims to develop Machine Learning models to predict 30-day unplanned readmissions in cancer patients treated at a private hospital in Brazil. METHODS: This retrospective cohort study included admission records of hospitalizations lasting >24 hours, with a corresponding diagnosis of …

us, br (code pays fourni par la source)

The Adoption and Integration of Artificial Intelligence in Diagnostics Across Europe

Denis Horgan, Carolina Reduzzi, Ivica Belina, Jonathan A. Lal et autres

Background: Artificial intelligence (AI) is increasingly integrated into diagnostic pathways across Europe, particularly within precision oncology. However, adoption remains uneven across regions. Methods: This review draws on national registries, institutional reports, reimbursement frameworks, and scientific literature to assess AI-based diagnostic tools, liquid …

in, be, us, br, Algérie, Égypte (code pays fourni par la source)

Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Roberto Carmagnani Pestana, Justin Tyler Moyers, Jason Roszik, Shiraj Sen et autres

Summary of response outcomes across subgroups

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Roberto Carmagnani Pestana, Justin Tyler Moyers, Jason Roszik, Shiraj Sen et autres

Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.

Supplementary Tables S1-S4 from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Justin Tyler Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong et autres

Supplement Table 1: Histologic Make-up of common sarcomas Supplement Table 2: List of common alterations among URS population by frequency Supplement Table 3: Sarcomas experiencing without clinical benefit (e.g. SD for <6 months or PD as best response) Supplement Table 4: Immunotherapy …

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis

Douglas Dias e Silva, Laura Sambugaro Pernomian, Matheus de Medeiros Fernandes, Miguel Chaves Lenzi et autres

INTRODUCTION: Soft tissue sarcomas (STS) are a rare and diverse group of mesodermal-origin cancers with limited systemic treatment options in advanced-stage disease. Recent evidence suggests that combination therapies involving tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor (VEGFR) and …

br (code pays fourni par la source)

Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.

Irvin Yi, Pedro Gomes, Nicole Janell Hardy, Brandon Edward Rose et autres

11562 Background: Sorafenib has shown effectiveness in managing desmoid tumors. However, the optimal duration of systemic therapy and the outcomes following its discontinuation remain unknown. This study investigates the outcomes of patients who discontinued sorafenib, aiming to provide guidance for clinicians on …

us, br (code pays fourni par la source)

Tumor-agnostic therapies in a high-volume Brazilian center: Real-world challenges and opportunities.

Manuel Teixeira, Camila Bobato Lara Gismondi, Miguel Zugman, Fernando Moura et autres

e23304 Background: Advances in precision oncology led to the approval of tumor-agnostic therapies (TAT), challenging conventional drug development. Despite promising Phase I/II data leading to multiple drug approvals, real-world data remains scarce, hindering confirmation of reproducibility, especially in Latin America. Methods: In …

br (code pays fourni par la source)